Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + Bendamustine in AL Amyloidosis
NCT04943302Phase 2Withdrawn
- Sponsor
- Tufts Medical Center
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in systemic light chain amyloidosis, sponsored by Tufts Medical Center. Primary endpoint: Estimated Hematologic Response at 36 months. Planned start Sep 2022; status: withdrawn.
02
Drugs
isatuximab
03
Conditions
systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT04943302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04943302.